comparemela.com

Page 6 - Cytomegalovirus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Inborn Immunodeficiency Cause Discovered

Through genome analysis, scientists have discovered that T95R mutation in IRF4 was found to play a key role in inborn immunodeficiency condition.

Max delbrNational institutes of healthBiology of malignant lymphomas labUniversity of ulmUnited statesNational institutesInborn immunodeficienciesMalignant lymphomas labInborn immunodeficiencyRare disorderEpstein barr virus

Congenital CMV Linked to Pediatric Hyperdiploid ALL

Early congenital cytomegalovirus could be a modifiable risk factor for childhood hyperdiploid acute lymphoblastic leukemia but more research delineating a mechanism is warranted.

United statesBaylor college of medicineLos angelesJoseph wiemelsJennifer gerisNational institutes of healthUniversity of minnesotaKeck school of medicineUniversity of southern californiaUs department of defenseJama networkBaylor collegeKeck schoolSouthern californiaNational institutesAcute leukemia

What is the association between acute lymphoblastic leukemia and congenital cytomegalovirus infection?

Researchers evaluated the relationship between congenital cytomegalovirus (cCMV) infection and acute lymphoblastic leukemia (ALL).

United statesKateryna kon shutterstockMichigan biotrust for healthPediatric acute lymphoblasticImage creditMichigan biotrustIndustry focusAcute lymphoblastic leukemiaCytomegalovirus infectionDown syndromeRadiation exposure

State to require newborn CMV screenings in 2023

CMV is a common virus that can have lifelong impacts on your baby, so much so that the state will start requiring screenings in the new year.

United statesSamantha isaacsCrystal burnhamNorth florida momAbc action newsHillsborough countyTampa bay local newsNational cmv foundation

Takeda UK Ltd: NICE recommends LIVTENCITY? (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) refractory (with or without resistance) to prior therapies

Takeda UK Ltd. is pleased to announce that NICE has recommended the use of LIVTENCITY? (maribavir) as a twice daily oral treatment for adult patients with post-transplant cytomegalovirus (CMV)

United kingdomCity ofRachel millerEl chaerAnthony nolanPeter wheatleyMark harberSimon meadowcroftMaribavir smDrug administrationPrnewswire takeda united kingdom ltdBritish society of bloodRegulatory agencyTakeda pharmaceutical companyNational institute for healthTakeda pharmaceutical company limited

vimarsana © 2020. All Rights Reserved.